Tempest Therapeutics, Inc.TPSTNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank77
3Y CAGR+48.1%
5Y CAGR-7.6%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
+48.1%/yr
Annual compound
5Y CAGR
-7.6%/yr
Recent acceleration
Percentile
P77
Within normal range
vs 5Y Ago
0.7x
Contraction
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
202462.74%
2023-22.32%
202231.23%
202119.30%
2020-48.32%
201993.02%
2018-0.70%
2017-32.88%
201617.40%
2015-15.38%